Please wait while the formulary information is being retrieved.
DRUG IMAGES
HURRICAINE 20% SPRAY
HURRICAINE 20% LIQUID
HURRICAINE 20% GEL SYRINGE
HURRICAINE 20% GEL
The following indications for HURRICAINE (benzocaine) have been approved by the FDA:
Indications:
Administration of local anesthesia
Aphthous stomatitis
Denture stomatitis
Gingivostomatitis
Mouth irritation
Sore throat
Suppression of the gag reflex
Professional Synonyms:
Aphthous ulcer
Burning sensation of throat
Denture sore mouth
Gag reflex suppression
Oral irritation
Pharyngeal pain
Pharyngeal soreness
Sore throat symptom
Ulcerative stomatitis
Indications:
Administration of local anesthesia
Aphthous stomatitis
Denture stomatitis
Gingivostomatitis
Mouth irritation
Sore throat
Suppression of the gag reflex
Professional Synonyms:
Aphthous ulcer
Burning sensation of throat
Denture sore mouth
Gag reflex suppression
Oral irritation
Pharyngeal pain
Pharyngeal soreness
Sore throat symptom
Ulcerative stomatitis
The following dosing information is available for HURRICAINE (benzocaine):
No enhanced Dosing information available for this drug.
Benzocaine is administered orally as a lozenge or applied topically to mucous membranes as an aerosol spray, swab, gel, solution, cream, or ointment. The drug should not be administered as an injection. Benzocaine is commercially available alone or in fixed combination with other drugs (e.g., antitussives, analgesics, demulcents, other local anesthetics) in many dosage forms, some of which are intended for self-medication; the manufacturer's product labeling should be consulted for complete directions for appropriate dosage and administration of the specific product.
The smallest amount required to produce the desired response should be administered. Benzocaine lozenges are administered orally by dissolving the lozenge slowly in the mouth. For topical application, benzocaine may be applied to any accessible mucous membrane except for the eyes.
When using aerosol preparations, the amount of benzocaine contained in a single spray varies based on the concentration of the solution, amount of time the actuator is depressed, residual volume in the can, and spatial orientation of the can during administration. The manufacturer of benzocaine in fixed combination with butamben and tetracaine hydrochloride (Cetacaine(R)) recommends application directly to the site where pain control is required; it is not necessary to dry the tissue prior to application. The manufacturers of some topical benzocaine products intended for self-medication suggest that adults supervise children younger than 12 years of age during drug administration.
The smallest amount required to produce the desired response should be administered. Benzocaine lozenges are administered orally by dissolving the lozenge slowly in the mouth. For topical application, benzocaine may be applied to any accessible mucous membrane except for the eyes.
When using aerosol preparations, the amount of benzocaine contained in a single spray varies based on the concentration of the solution, amount of time the actuator is depressed, residual volume in the can, and spatial orientation of the can during administration. The manufacturer of benzocaine in fixed combination with butamben and tetracaine hydrochloride (Cetacaine(R)) recommends application directly to the site where pain control is required; it is not necessary to dry the tissue prior to application. The manufacturers of some topical benzocaine products intended for self-medication suggest that adults supervise children younger than 12 years of age during drug administration.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for HURRICAINE (benzocaine):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Long-acting Bupivacaine/Local Anesthetics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of other local anesthetics or use of other local anesthetics within 96 hours following long-acting bupivacaine may result in additive neurologic and cardiovascular effects. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also increase the risk of methemoglobinemia.(1,2) Non-liposomal bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally.(1) CLINICAL EFFECTS: Concurrent or use of local anesthetics with 96 hours of use of long-acting bupivacaine may result in neurologic and cardiovascular toxicity. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also result in methemoglobinemia.(1,2) Non-liposomal bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally.(1) PREDISPOSING FACTORS: Use of additional agents that are associated with methemoglobinemia may further increase the risk of methemoglobinemia.(1) Patients who are at increased risk of developing methemoglobinemia include those with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.(1) PATIENT MANAGEMENT: Avoid the use of other local anesthetics within 96 hours following the administration of long-acting bupivacaine. In patients for whom use is required, monitor for neurologic and cardiovascular effects. Also monitor for methemoglobinemia with use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine.(1,2) Non-liposomal bupivacaine may be administered in the same syringe as bupivacaine liposomal or injected immediately before bupivacaine liposomal as long as the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Lidocaine may be administered 20 minutes or more prior to bupivacaine. It is unknown if other local anesthetics may be used without compromising the release characteristic of bupivacaine liposomal.(1) DISCUSSION: Concurrent use of other local anesthetics or use of other local anesthetics within 96 hours following long-acting bupivacaine may result in additive neurologic and cardiovascular effects. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also increase the risk of methemoglobinemia.(1,2) Non-liposome bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally. Lidocaine may be administered 20 minutes or more prior to bupivacaine. It is unknown if other local anesthetics may be used without compromising the release characteristic of bupivacaine liposomal.(1) |
BUPIVACAINE LIPOSOME, EXPAREL, XARACOLL, ZYNRELEF |
There are 0 moderate interactions.
The following contraindication information is available for HURRICAINE (benzocaine):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Methemoglobinemia |
There are 5 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Glucose-6-phosphate dehydrogenase (g6Pd) deficiency |
| Hemolytic anemia from pyruvate kinase and g6PD deficiencies |
| NADH methemoglobin reductase deficiency |
| Pregnancy |
| Systemic mastocytosis |
There are 0 moderate contraindications.
The following adverse reaction information is available for HURRICAINE (benzocaine):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 2 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Angioedema |
| Rare/Very Rare |
|---|
|
Methemoglobinemia |
There are 6 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Contact dermatitis Erythema Mouth irritation Pruritus of skin Skin rash Urticaria |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for HURRICAINE (benzocaine):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for HURRICAINE (benzocaine):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for HURRICAINE (benzocaine)'s list of indications:
| Aphthous stomatitis | |
| K12.0 | Recurrent oral aphthae |
| Denture stomatitis | |
| K12.1 | Other forms of stomatitis |
| Gingivostomatitis | |
| K05.10 | Chronic gingivitis, plaque induced |
| Mouth irritation | |
| K13.79 | Other lesions of oral mucosa |
| Sore throat | |
| R07.0 | Pain in throat |
Formulary Reference Tool